Clinically relevant doses of tiludronate do not affect bone remodelling in pasture-exercised horses.

Background: Bisphosphonates are widely used in equine athletes to reduce lameness associated with skeletal disorders. Widespread off-label use has led to concern regarding potential negative effects on bone healing, but little evidence exists to support or refute this.

Objectives: To investigate the influence of clinically relevant doses of tiludronate on bone remodelling and bone healing.

Cortical porosity occurs at varying degrees throughout the skeleton in rats with chronic kidney disease.

Cortical porosity develops in chronic kidney disease (CKD) and increases with progressing disease. Cortical porosity is likely a prominent contributor to skeletal fragility/fracture. The degree to which cortical porosity occurs throughout the skeleton is not fully known.

Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease.

Purpose: Patients with chronic kidney disease (CKD) have high risk of fracture in part due to cortical bone deterioration. The goal of this study was to assess the impact of two different bisphosphonates and dosing regimens on cortical microstructure (porosity, thickness, area) and bone mechanical properties in animal models of CKD.

Methods: In experiment 1, Male Cy/+ (CKD) rats were treated with either a single dose or ten fractionated doses of zoledronate at 18 weeks of age.

The combination of aging and chronic kidney disease leads to an exacerbated cortical porosity phenotype.

Purpose: Chronic kidney disease (CKD) and aging are each independently associated with higher fracture risk. Although CKD is highly prevalent in the aging population, the interaction between these two conditions with respect to bone structure and mechanics is not well understood. The purpose of this study was to examine cortical porosity and mechanical properties in skeletally mature young and aging mice with CKD.